An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies

References

• Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39(4):131–134.
   PubMedGoogle Scholar
• Sarsour K, Beckley-Kartey S, Melega S, et al. Rituximab utilization for approved and off-label nononcology indications and patients’ experiences with the patient alert card. Pharmacol Res Perspect. 2020;8(1):e00555.
   PubMed Web of Science ®Google Scholar
• Kroon FPB, Najm A, Alunno A, et al., Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis. 2022;81(3):422–432.
   PubMed Web of Science ®Google Scholar
• Rbm L, Kroon FPB, Alunno A, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022. DOI:10.1136/annrheumdid-2021-222006.
   Web of Science ®Google Scholar
• Curtis JR, Johnson SR, Anthony DD, et al. American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 4. Arthritis Rheumatol. 2022;74(5):e21–36.
   PubMed Web of Science ®Google Scholar
• Mehta P, Gasparyan AY, Zimba O, et al. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol. 2022;41: 2893–2910.
   PubMed Web of Science ®Google Scholar
• FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80(4):527–538.
   PubMed Web of Science ®Google Scholar
• Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–26.
   PubMedGoogle Scholar
• Raiker R, DeYoung C, Pakhchanian H, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057–1066.
   PubMed Web of Science ®Google Scholar
• Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis. 2021;80(9):1137–1146.
   PubMed Web of Science ®Google Scholar
• Alpizar-Rodriguez D, Irazoque-Palazuelos F, Rodriguez-Reyne TS, et al. Pos1242 factors associated with mortality in patients with rheumatic diseases and covid-19 in Mexico. Ann Rheum Dis. 2021;80(904):904.1–904.
   Google Scholar
• Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–942.
   PubMed Web of Science ®Google Scholar
• Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID cohort collaborative. Lancet Rheumatol. 2022;4(1):e33–41.
   PubMedGoogle Scholar
• Bower H, Frisell T, Di Giuseppe D, et al., Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021;80(8):1086–1093.
   PubMed Web of Science ®Google Scholar
• Elliott P, Eales O, Steyn N, et al. Twin peaks: the Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England [online]. (2022). Available at: https://spiral.imperial.ac.uk/bitstream/10044/1/96170/8/REACT-1_R19_Final.pdf [Accessed 2022 Apr 23
   Google Scholar
• Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–1312.
   PubMed Web of Science ®Google Scholar
• Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021;100(11):2805–2812.
   PubMed Web of Science ®Google Scholar
• Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–941.
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Bakasis A-D, Goules AV, et al. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun. 2021;125(102743):102743.
   PubMedGoogle Scholar
• Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: b cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345–1350.
   PubMed Web of Science ®Google Scholar
• Connolly CM, Boyarsky BJ, Ruddy JA, et al. Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series. Ann Intern Med. 2021;174(9):1332–1334.
   PubMed Web of Science ®Google Scholar
• Grainger R, Kim AH, Conway R, et al. in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191–204.
   PubMed Web of Science ®Google Scholar
• Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3(11):e789–97.
   PubMedGoogle Scholar
• Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–462.
   PubMed Web of Science ®Google Scholar
• Notarbartolo S, Ranzani V, Bandera A, et al. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci Immunol. 2021;6(62):eabg502.
   Web of Science ®Google Scholar
• Spellberg B, Edwards JE. Type 1/Type 2 Immunity in Infectious Diseases. Clin Inf Dis. 2001;32(1):76–102.
   PubMed Web of Science ®Google Scholar
• Marty PK, Van Keulen VP, Erskine CL, et al. Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-Cell depleting therapy. Front Immunol. 2022;28(13):834981.
   Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634.
   PubMed Web of Science ®Google Scholar
• Bitoun S, Avouac J, Henry J, et al. Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses. RMD Open. 2022;8(1):e002308.
   PubMed Web of Science ®Google Scholar
• Jyssum I, Kared H, Tran TT, et al., Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022;4(3):e177–87.
   PubMedGoogle Scholar
• Ugarte-Gil MF, Alarcón GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis. 2022;81(7):970–978.
   PubMed Web of Science ®Google Scholar
• Wolfromm A, Mittaine B, Gandrille N, et al. Home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience. Blood. 2017;130(1):4676.
   Google Scholar
• Fouda GE, Rituximab Hypersensitivity: BS. From clinical presentation to management. Front Pharmacol. 2020;11(572863). DOI:10.3389/fphar.2020.572863
   Google Scholar
• RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:665–676.
   PubMed Web of Science ®Google Scholar
• Anti-SARS-CoV-2 monoclonal antibodies [online]. (2022). Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/ [Accessed 2022 Aug 9
   Google Scholar
• Levin MJ, Ustianowski A, De Wit S, et al., Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19. New Eng J Med. 2022;386(23):2188–2200.
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. New Eng J Med. 2022;386(15):1475–1477.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. New Eng J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Solidarity Trial WHO. Consortium. repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. New Eng J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Inf Dis. 2022;22(2):209–221.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. New Eng J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New Eng J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the management of rheumatic disease in adult patients during the COVID‐19 pandemic: version 2. Arthritis Rheumatol. 2020;72(9):e1–2.
   PubMed Web of Science ®Google Scholar